C

Curacle Co Ltd
KOSDAQ:365270

Watchlist Manager
Curacle Co Ltd
KOSDAQ:365270
Watchlist
Price: 9 480 KRW -1.25% Market Closed
Market Cap: ₩199.2B

Net Margin

-1 535.2%
Current
Declining
by 881.5%
vs 3-y average of -653.7%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 535.2%
=
Net Income
₩-17.5B
/
Revenue
₩1.1B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 535.2%
=
Net Income
₩-17.5B
/
Revenue
₩1.1B

Peer Comparison

Country Company Market Cap Net
Margin
KR
Curacle Co Ltd
KOSDAQ:365270
201.7B KRW
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
168.8B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.9B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.2B USD
Loading...

Market Distribution

Lower than 99% of companies in Korea
Percentile
1st
Based on 2 632 companies
1st percentile
-1 535.2%
Low
-168 471.3% — -2.9%
Typical Range
-2.9% — 5.8%
High
5.8% — 21 012.5%
Distribution Statistics
Korea
Min -168 471.3%
30th Percentile -2.9%
Median 1.9%
70th Percentile 5.8%
Max 21 012.5%

Curacle Co Ltd
Glance View

Market Cap
199.2B KRW
Industry
Biotechnology

Curacle Co., Ltd. is engaged in the business of research and experimental development on medical sciences and pharmacy. The company is headquartered in Seoul, Seoul and currently employs 39 full-time employees. The company went IPO on 2021-07-22. The firm researches and develops synthetic drugs CU06-RE, CU01, and natural drug CU03 as new drugs for intractable vascular diseases. The Company’s drugs are used for diabetic macular edema (DME), diabetic nephropathy (DN), and wet age-related macular degeneration (wet AMD). In addition, the Company uses the SOLVADYS platform technology, a platform technology for the development of vascular endothelial dysfunction blockers.

Intrinsic Value
1 474.09 KRW
Overvaluation 84%
Intrinsic Value
Price
C
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-1 535.2%
=
Net Income
₩-17.5B
/
Revenue
₩1.1B
What is Curacle Co Ltd's current Net Margin?

The current Net Margin for Curacle Co Ltd is -1 535.2%, which is below its 3-year median of -653.7%.

How has Net Margin changed over time?

Over the last 3 years, Curacle Co Ltd’s Net Margin has decreased from -52.5% to -1 535.2%. During this period, it reached a low of -1 649.7% on Jun 30, 2025 and a high of -52.5% on Aug 30, 2022.

Back to Top